Serotonin Receptor Agonists
"Serotonin Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS.
| Descriptor ID |
D017366
|
| MeSH Number(s) |
D27.505.519.625.850.800 D27.505.696.577.850.800
|
| Concept/Terms |
Serotonin Receptor Agonists- Serotonin Receptor Agonists
- Agonists, Serotonin Receptor
- 5-HT Agonists
- 5 HT Agonists
- Agonists, 5-HT
- 5-Hydroxytryptamine Agonists
- 5 Hydroxytryptamine Agonists
- Agonists, 5-Hydroxytryptamine
- 5-Hydroxytrytamine Agonist
- 5 Hydroxytrytamine Agonist
- Agonist, 5-Hydroxytrytamine
- Receptor Agonists, Serotonin
- Serotonergic Agonists
- Agonists, Serotonergic
- Serotonin Agonist
- Agonist, Serotonin
- Serotonin Agonists
- Agonists, Serotonin
- Serotonin Receptor Agonist
- Agonist, Serotonin Receptor
- Receptor Agonist, Serotonin
- 5-HT Agonist
- 5 HT Agonist
- Agonist, 5-HT
- Serotonergic Agonist
- Agonist, Serotonergic
|
Below are MeSH descriptors whose meaning is more general than "Serotonin Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Serotonin Receptor Agonists".
This graph shows the total number of publications written about "Serotonin Receptor Agonists" by people in this website by year, and whether "Serotonin Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 1 | 0 | 1 |
| 2002 | 8 | 1 | 9 |
| 2003 | 7 | 3 | 10 |
| 2004 | 15 | 2 | 17 |
| 2005 | 5 | 1 | 6 |
| 2006 | 3 | 2 | 5 |
| 2007 | 5 | 0 | 5 |
| 2008 | 7 | 1 | 8 |
| 2009 | 6 | 1 | 7 |
| 2011 | 1 | 1 | 2 |
| 2012 | 4 | 0 | 4 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Serotonin Receptor Agonists" by people in Profiles.
-
Mathew PG, Klein BC. Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. Headache. 2019 09; 59(8):1421-1426.
-
Maasumi K, Tepper SJ, Rapoport AM. New treatments for headache. Neurol Sci. 2017 May; 38(Suppl 1):145-156.
-
Tepper SJ. Medication overuse headache. Headache. 2014 Jan; 54(1):203.
-
Landy SH, Tepper SJ, Schweizer E, Almas M, Ramos E. Outcome for headache and pain-free nonresponders to treatment of the first attack: a pooled post-hoc analysis of four randomized trials of eletriptan 40 mg. Cephalalgia. 2014 Apr; 34(5):376-81.
-
Almas M, Tepper SJ, Landy S, Schweizer E, Ramos E. Consistency of eletriptan in treating migraine: Results of a randomized, within-patient multiple-dose study. Cephalalgia. 2014 Feb; 34(2):126-35.
-
Stillman MJ, Tepper DE, Tepper SJ, Cho L. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 2: review of headache medications, drug-drug interactions, QTc prolongation, and other arrhythmias. Headache. 2013 Jan; 53(1):217-224.
-
Stillman MJ, Tepper S, Tepper DE, Cho L. QT prolongation, Torsade de Pointes, myocardial ischemia from coronary vasospasm, and headache medications. Part 1: review of serotonergic cardiac adverse events with a triptan case. Headache. 2013 Jan; 53(1):208-216.
-
Kline AE, Olsen AS, Sozda CN, Hoffman AN, Cheng JP. Evaluation of a combined treatment paradigm consisting of environmental enrichment and the 5-HT1A receptor agonist buspirone after experimental traumatic brain injury. J Neurotrauma. 2012 Jul 01; 29(10):1960-9.
-
Tepper SJ. Serotonin syndrome: SSRIs, SNRIs, triptans, and current clinical practice. Headache. 2012 Feb; 52(2):195-7.
-
Ward SJ, Raffa RB. Rimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies. Obesity (Silver Spring). 2011 Jul; 19(7):1325-34.